Posts

Selecting the Right Platform for Your Antibody Discovery Project

November 17, 2022

Contributed by John Charpentier, Ph.D. and Li Hui, M.D., Ph.D. The variety of technology platforms available for therapeutic antibody discovery can be both exciting and daunting. Here we provide some general guidelines to help investigators understand their capabilities and applications. Since the introduction of hybridoma technology in the 1970s, numerous antibody discovery platforms have been […]

Read More

Development History of Immunodeficient Mice and Their Research Applications

October 25, 2022

By John Charpentier, Ph.D. October 25, 2022 Since the characterization of the nude mouse in 1962, genetic mouse models of immunodeficiency have been increasingly developed, diversified, and utilized for both basic discovery research and preclinical studies of therapeutic candidates. Today, highly immunodeficient, genetically-engineered mouse models are invaluable tools for basic biomedical research, especially for the […]

Read More

Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis

September 29, 2022

By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing Zhong and colleagues at Jinan University in Guangzhou, China report that a lipid binding protein called ORP4L, which is expressed in adult T cell leukemia (ATL) cells but not normal […]

Read More

Research Impact: Custom Biocytogen mouse models used to identify critical mediator of inflammation-driven metastases

September 7, 2022

By John Charpentier, Ph.D. September 7, 2022 While metastases are ultimately responsible for the large majority of cancer deaths, most oncology drugs in development target primary tumors, and few specifically prevent metastasis. Although surgical resection of solid tumors is an effective early treatment intervention, the resulting inflammation can promote metastasis by increasing adhesion of circulating […]

Read More

2022 Popular Mouse Models and Cell Lines

August 11, 2022

Biocytogen’s advanced genome editing technologies have been leveraged by our own development scientists to create hundreds of animal and cell models used in biomedical research all over the world. 13 years since our founding, Biocytogen’s catalog of off-the-shelf gene-edited animal models, BioMice, now contains more than 450 strains. From knock-outs to humanized knock-ins, our models […]

Read More

First Half of 2022 Publications Highlight

August 8, 2022

Our off-the-shelf and custom animal and cell models are advancing cutting-edge biomedical research every day. One measure of this impact is how often they appear in high impact publications and journals. Check out the list of studies published so far this year which feature Biocytogen models: B-hCD3E Mice Zhang, R., Zhang, J., Zhou, X. et […]

Read More

Team Building in the White Mountains

July 27, 2021

July 27, 2021 – Biocytogen Boston Corporation held a team-building retreat at the Grand View Mountain Resort in New Hampshire last week. The event, propelled by the extensive recent growth of the USA Team, offered the opportunity for employees to engage with new colleagues across all departments, participate in outdoor recreational activities, and enjoy the […]

Read More

Syngeneic Mouse Models and Humanized Immune-Checkpoint Mice

June 17, 2020

Why do we need Syngeneic Mouse Models? To test potential immuno-oncology therapeutics in vivo, it is necessary to ensure that the disease model used has an intact immune system. Immunotherapeutics work with the body’s immune system to fight cancer cells. Often through inhibiting specific cell receptors called immune checkpoints, immunotherapeutics seek to bind to receptors […]

Read More

Gene Targeting Service Verified with Industry-leading Quality Control Measures

March 12, 2020

  At Biocytogen, we take pride in our quality control measures when we target and edit genes for our mouse models and drug development endeavors. From preventing potentially disastrous results before they occur to instituting reliable, tried-and-true protocols, proper attention to quality control when gene-editing can save clients both time and resources. For example, based […]

Read More

Knock In and Knock Out Mice as Powerful Disease Models

March 3, 2020

Why Do We Care About Gene-edited Mice? The generation of knockout and knock-in animal models has allowed not only disease research but also the development of disease-fighting drugs. The Nobel Prize for Physiology and Medicine recognized Evans, Smithies, and Capecchi for their joint effort in creating the first knockout mouse over two decades ago in […]

Read More

Back to top